Lang GE, Stahl A, Voegeler J, et al. - In the present study, the researchers sought to assess long-term anatomical and functional outcomes in proliferative diabetic retinopathy (PDR) patients under real-life conditions, prior to the approval of ranibizumab for PDR. Seventy-three PDR patients (28 in the ranibizumab group; 20 in the PRP group; 25 in the combination group) were involved in the observational follow-up phase and treated at the discretion of the investigators. Visual acuity (VA) measurements and retinal imaging were conducted at Months 12, 18, and 24. In PDR patients, discontinuing ranibizumab treatment may result in an increase in neovascularization area and VA loss. To maintain disease control, strict monitoring of disease activity and continued treatment beyond the first year is required.